Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21620360 | 0.99 | STING1 (0.42) | STING1ADORA2AHPGDSNNMTSMN1; SMN2 | |
| SCHEMBL27207460 | 0.88 | STING1 (0.41) | STING1ADORA2AKMT2A | |
| SCHEMBL27204002 | 0.88 | STING1 (0.41) | STING1ADORA2AKMT2A | |
| SCHEMBL21620363 | 0.88 | STING1 (0.39) | STING1ADORA2AHPGDS | |
| SCHEMBL28752004 | 0.87 | STING1 (0.42) | STING1ADORA2A | |
| SCHEMBL29689171 | 0.87 | STING1 (0.42) | STING1ADORA2A | |
| SCHEMBL28752005 | 0.87 | STING1 (0.42) | STING1ADORA2A | |
| SCHEMBL21630047 | 0.83 | KDM4E (0.41) | STING1ADORA2A | |
| SCHEMBL21616395 | 0.82 | STING1 (0.47) | STING1ADORA2A | |
| SCHEMBL21620380 | 0.81 | DRD3 (0.39) | STING1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| WO-2020010451-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | STING1, MAVS, IRF3 | STING1 1/4885ADORA2A 1384/4885HPGDS 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.